IS5946A - Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform - Google Patents

Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform

Info

Publication number
IS5946A
IS5946A IS5946A IS5946A IS5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A
Authority
IS
Iceland
Prior art keywords
amorphous
transformed
semi
particles
crystalline form
Prior art date
Application number
IS5946A
Other languages
English (en)
Inventor
Bisrat Mikael
Moshashee Saeed
Nyqvist Håkan
Demirbüker Mustafa
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5946A publication Critical patent/IS5946A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
IS5946A 1998-11-23 2001-05-18 Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform IS5946A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (1)

Publication Number Publication Date
IS5946A true IS5946A (is) 2001-05-18

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5946A IS5946A (is) 1998-11-23 2001-05-18 Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform

Country Status (27)

Country Link
US (1) US6475524B1 (is)
EP (1) EP1133285B1 (is)
JP (1) JP4447169B2 (is)
KR (1) KR100697780B1 (is)
CN (1) CN1198592C (is)
AT (1) ATE318583T1 (is)
AU (1) AU767313B2 (is)
BR (1) BR9915592A (is)
CA (1) CA2349633C (is)
CY (1) CY1105609T1 (is)
CZ (1) CZ20011778A3 (is)
DE (1) DE69930158T2 (is)
DK (1) DK1133285T3 (is)
EE (1) EE200100275A (is)
ES (1) ES2258865T3 (is)
HU (1) HUP0104182A2 (is)
IL (2) IL143040A0 (is)
IS (1) IS5946A (is)
NO (1) NO20012514L (is)
NZ (1) NZ511494A (is)
PL (1) PL348523A1 (is)
PT (1) PT1133285E (is)
SE (1) SE9804000D0 (is)
SK (1) SK7032001A3 (is)
TR (1) TR200101424T2 (is)
WO (1) WO2000030614A1 (is)
ZA (1) ZA200103946B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (en) * 2000-12-26 2007-07-04 Takeda Pharmaceutical POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
EP1401563B2 (en) * 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1753734A1 (en) 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
US8585943B2 (en) * 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
EP2393488B1 (en) 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
KR101742252B1 (ko) 2009-07-15 2017-05-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 비페닐 화합물의 결정질 유리 염기형
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
EP3173080B1 (en) 2010-08-27 2019-12-11 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
EP2968312B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
DK3749291T3 (da) 2018-02-08 2024-04-08 Univ Southern California Fremgangsmåder til permeabilisering af blod-hjerne-barrieren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
EP0817620B1 (en) * 1995-03-28 2002-01-30 Fidia Advanced Biopolymers, S.R.L. Nanospheres comprising a biocompatible polysaccharide
WO1998041193A1 (en) 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates

Also Published As

Publication number Publication date
EE200100275A (et) 2002-10-15
CA2349633A1 (en) 2000-06-02
SK7032001A3 (en) 2001-11-06
NZ511494A (en) 2003-11-28
PL348523A1 (en) 2002-06-03
ES2258865T3 (es) 2006-09-01
JP4447169B2 (ja) 2010-04-07
KR20010080534A (ko) 2001-08-22
CZ20011778A3 (cs) 2001-08-15
ZA200103946B (en) 2002-10-30
CA2349633C (en) 2009-06-02
IL143040A (en) 2009-09-01
SE9804000D0 (sv) 1998-11-23
DE69930158T2 (de) 2006-11-16
KR100697780B1 (ko) 2007-03-21
BR9915592A (pt) 2001-08-07
AU767313B2 (en) 2003-11-06
WO2000030614A1 (en) 2000-06-02
AU2010400A (en) 2000-06-13
HUP0104182A2 (hu) 2002-03-28
JP2002530319A (ja) 2002-09-17
EP1133285B1 (en) 2006-03-01
NO20012514L (no) 2001-07-19
NO20012514D0 (no) 2001-05-22
CY1105609T1 (el) 2010-07-28
US6475524B1 (en) 2002-11-05
PT1133285E (pt) 2006-06-30
DK1133285T3 (da) 2006-06-06
TR200101424T2 (tr) 2001-12-21
DE69930158D1 (de) 2006-04-27
CN1198592C (zh) 2005-04-27
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
IL143040A0 (en) 2002-04-21
EP1133285A1 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
IS5946A (is) Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform
DK1133284T3 (da) Fremgangsmåde til fremstilling af krystallinske partikler
WO2002055017A3 (en) Method of treating autoimmune diseases
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
DE60018881D1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2003000241A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika; corticosteroiden und betamimetika zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
DE60001640D1 (de) Dreidimensionale struktur enthaltend hyaluronsäurederivat, hergestellt durch die technik von superkritischen antilösungsmitteln
SE9603725D0 (sv) New teatment
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
ATE309811T1 (de) Analgetikum aus schlangengift
HUP0203032A2 (hu) Eplerenon gyorsan oldódó kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9912581A (pt) Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE474552T1 (de) ßFESTE DOSIERUNGSFORM ZUR OKULAREN APPLIKATION EINER WIRKSUBSTANZ, LÖSLICHE, FESTE OPHTHALMISCHE EINLAGE SOWIE HERSTELLUNGSVERFAHREN DAFÜRß
CN1069196C (zh) 利福平在制备治疗淋病用的药物中的应用
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
RU93044740A (ru) Гетероциклические соединения, способ их получения, применение и фармацевтическая композиция